STOCK TITAN

Synaptogenix, Inc. - SNPX STOCK NEWS

Welcome to our dedicated page for Synaptogenix news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix stock.

Synaptogenix, Inc. (NASDAQ: SNPX) is an emerging clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. The company leverages its lead drug candidate, Bryostatin-1, in addressing various challenging conditions such as Alzheimer's disease, Fragile X syndrome, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and traumatic brain injury.

Synaptogenix is currently conducting clinical and preclinical trials to evaluate the efficacy and safety of Bryostatin-1. This drug, which activates protein kinase C (PKC), has shown potential in promoting synaptic growth, reducing inflammation, and aiding cognitive function. Recent achievements include partnering with the Cleveland Clinic for a Phase 1 trial of Bryostatin-1 aimed at cognitive impairment in MS and discovering potential benefits in treating ALS.

The company has also gained significant attention from the research community, with notable publications in esteemed journals like the Journal of Alzheimer's Disease and involvement in high-profile scientific forums. Leveraging its substantial financial resources, Synaptogenix continues to explore additional therapeutic avenues and partnerships, including a significant stake in Cannasoul Analytics, aiming to develop cannabinoid-based treatments.

Synaptogenix’s financial health is stable, bolstered by approximately $35.8 million as of March 31, 2023, and $33 million as of June 30, 2023, ensuring continuous development of its drug candidates. The company's recent reverse stock split aligns with strategic efforts to maintain NASDAQ compliance and increase stock value.

Rhea-AI Summary

Synaptogenix (Nasdaq: SNPX) announced changes to its Scientific Advisory Board (SAB) ahead of the Phase 2b clinical trial data for Bryostatin-1 in advanced Alzheimer's patients. The SAB includes experts such as Dr. George Perry and Dr. Marwan Sabbagh, who will guide the company's therapeutic developments. CEO Alan Tuchman emphasized the critical expertise of the SAB in preparing for the upcoming data. The company has also received Orphan Drug Designation for Bryostatin-1 targeting Fragile X syndrome, enhancing its research credentials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
management clinical trial
-
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) announced a corporate update conference call scheduled for July 26, 2022, at 4:30 PM ET. The call will be led by CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, with a live Q&A session following their remarks. The call will discuss updates on the company's development of regenerative therapeutics for neurodegenerative disorders, particularly focusing on Bryostatin-1 for Multiple Sclerosis and Alzheimer's disease. Forward-looking statements regarding clinical trials are included, highlighting potential risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) has initiated dosing in its open-label dose optimization clinical trial for Bryostatin-1, aimed at treating Alzheimer's disease (AD). This trial follows promising results from two pilot Phase 2 studies showing significant cognitive improvements over placebo. The company plans to release topline data from its NIH-sponsored Phase 2b trial in Q4 2022. CEO Alan Tuchman expressed optimism about Bryostatin's potential to address synaptic loss, while emphasizing the need for dose optimization to enhance treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
Rhea-AI Summary

Synaptogenix, a biopharmaceutical company focused on neurodegenerative disorders, announced that Dr. Daniel Alkon will present at the Cell Symposium in Spain on May 17, 2022. The presentation is titled "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." This research aims to extend the therapeutic benefits of Bryostatin for Alzheimer's patients. Currently, the company is conducting a NIH-supported Phase 2 trial for advanced Alzheimer's patients who have shown improvement with Bryostatin treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.97%
Tags
conferences
-
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) has completed enrollment of 100 patients in its NIH-sponsored Phase 2b clinical trial of Bryostatin-1, targeting advanced Alzheimer's disease. Topline results are expected in Q4 2022. The Data Safety Monitoring Board reported no adverse safety issues, suggesting a favorable safety profile for the drug. Past trials indicated significant cognitive enhancement for treated patients. With extended dosing in the current trial, the company anticipates promising outcomes that could lead to further clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) announced the publication of a peer-reviewed article highlighting Bryostatin's potential to enhance blood vessel health, critical for Alzheimer's disease (AD) treatment. The study, led by researchers from Thomas Jefferson University with NIH collaboration, shows Bryostatin increased micro-vessels in AD mouse models, indicating promise for ongoing Phase 2b clinical trials of Bryostatin-1 in AD patients. The findings emphasize Bryostatin's dual benefits in restoring vascular health and oxidative balance, presenting a hopeful prospect for Alzheimer's care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) announced Dr. Daniel Alkon's presentation at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on March 29, 2022, at 2 PM ET. His talk focuses on 'Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration.' The company is optimistic about its Phase 2b clinical trial of Bryostatin-1 for advanced Alzheimer's, supported by new peer-reviewed data indicating cognitive restoration. Synaptogenix is committed to developing therapies for neurodegenerative disorders, backed by prior studies on Bryostatin's effects on conditions like Fragile X syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
-
Rhea-AI Summary

Synaptogenix (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present on "Regenerative Therapeutics" at the Sachs Neuroscience Innovation Forum on March 22, 2022, at 8 am ET. The company reported promising results from its Phase 2 clinical trial of Bryostatin for advanced Alzheimer's patients, showing significant improvements in cognitive scores. The ongoing NIH-supported Phase 2B trial will further investigate Bryostatin’s effects. Synaptogenix is also planning trials for Fragile X syndrome and multiple sclerosis. Presentation details are available online and via social media.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Synaptogenix, Inc. (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022) on March 15, 2022. His presentation covers the clinical results of Bryostatin in treating advanced Alzheimer’s disease and explores its potential for other neurodegenerative disorders, including Parkinson’s and multiple sclerosis. Currently, Bryostatin-1 is under a six-month NIH-sponsored trial for Alzheimer’s. This research could broaden the therapeutic applications of Bryostatin-1 beyond Alzheimer’s.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
Rhea-AI Summary

Synaptogenix, Inc. (SNPX) announced plans to develop Bryostatin-1 for treating multiple sclerosis (MS), marking its third indication alongside Alzheimer's disease and Fragile X syndrome. The company will collaborate with the Cleveland Clinic for a clinical trial focused on safety and efficacy. Bryostatin-1 aims to address synaptic loss in MS patients, a gap in existing therapies. This collaboration aligns with Synaptogenix's strategic goal to advance clinical development through partnerships. The company has a significant safety database from prior studies in over 1,500 individuals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags

FAQ

What is the current stock price of Synaptogenix (SNPX)?

The current stock price of Synaptogenix (SNPX) is $3.035 as of December 24, 2024.

What is the market cap of Synaptogenix (SNPX)?

The market cap of Synaptogenix (SNPX) is approximately 4.1M.

What is Synaptogenix, Inc. focused on?

Synaptogenix, Inc. focuses on developing therapies for neurodegenerative diseases, primarily through its lead drug candidate, Bryostatin-1.

What are the main conditions Synaptogenix targets with Bryostatin-1?

Bryostatin-1 is being tested for effectiveness in conditions such as Alzheimer's disease, Fragile X syndrome, multiple sclerosis, amyotrophic lateral sclerosis, and traumatic brain injury.

What recent collaboration has Synaptogenix entered into?

Synaptogenix has partnered with the Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 for treating cognitive impairment in multiple sclerosis.

What financial resources does Synaptogenix have to fund its operations?

As of March 31, 2023, Synaptogenix had approximately $35.8 million and $33 million as of June 30, 2023, ensuring it has ample resources for ongoing development.

What recent study findings support the potential of Bryostatin-1?

Recent independent studies indicate that Bryostatin-1 may be a promising treatment for ALS, showing significant improvements in gene expression and cellular viability in preclinical models.

What is the significance of Synaptogenix's partnership with Cannasoul Analytics?

The partnership with Cannasoul Analytics aims to develop cannabinoid-based therapeutics, enhancing the potential for innovative treatments in various medical conditions.

How is Synaptogenix ensuring compliance with NASDAQ regulations?

Synaptogenix executed a reverse stock split to increase its per-share trading price, helping to maintain compliance with NASDAQ’s minimum bid price requirement.

What are the potential benefits of Bryostatin-1 in Alzheimer's disease?

Bryostatin-1 has shown potential to prevent cognitive decline in advanced Alzheimer's disease patients, as demonstrated in Phase 2 clinical trials.

Has Synaptogenix received any accolades or recognition in the scientific community?

Yes, Synaptogenix's research and findings have been published in reputable journals, and its leadership has been recognized at prominent scientific forums.

What are the forward-looking statements and risks related to Synaptogenix?

Forward-looking statements involve risks and uncertainties, including the potential success of clinical trials, regulatory approval, and the company's ability to secure adequate financing.

Synaptogenix, Inc.

Nasdaq:SNPX

SNPX Rankings

SNPX Stock Data

4.11M
1.33M
1.95%
0.29%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK